Date of download: 11/12/2016 Copyright © The American College of Cardiology. All rights reserved. From: Effectiveness of In-Laboratory High-Dose Clopidogrel Loading Versus Routine Pre-Load in Patients Undergoing Percutaneous Coronary Intervention: Results of the ARMYDA-5 PRELOAD (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) Randomized Trial J Am Coll Cardiol. 2010;56(7): doi: /j.jacc Figure Legend: Design of ARMYDA-5 PRELOAD Trial CABG = coronary artery bypass grafting; CK-MB = creatine kinase-MB; MI = myocardial infarction; NSTE-ACS = non–ST-segment elevation acute coronary syndrome; PCI = percutaneous coronary intervention; PRU = P2Y 12 reaction units; Rx = treatment; TVR = target vessel revascularization.

Date of download: 11/12/2016 Copyright © The American College of Cardiology. All rights reserved. From: Effectiveness of In-Laboratory High-Dose Clopidogrel Loading Versus Routine Pre-Load in Patients Undergoing Percutaneous Coronary Intervention: Results of the ARMYDA-5 PRELOAD (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) Randomized Trial J Am Coll Cardiol. 2010;56(7): doi: /j.jacc Figure Legend: Primary Study End Point Thirty-day occurrence of death, myocardial infarction, target vessel revascularization in patients receiving 600-mg clopidogrel in-lab load or pre- load. MACE = major adverse cardiac events; PCI = percutaneous coronary intervention.

Date of download: 11/12/2016 Copyright © The American College of Cardiology. All rights reserved. From: Effectiveness of In-Laboratory High-Dose Clopidogrel Loading Versus Routine Pre-Load in Patients Undergoing Percutaneous Coronary Intervention: Results of the ARMYDA-5 PRELOAD (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) Randomized Trial J Am Coll Cardiol. 2010;56(7): doi: /j.jacc Figure Legend: Individual Components of the Primary End Point Incidence of adverse events was mainly due to periprocedural myocardial infarction (MI) in both arms. TVR = target vessel revascularization.

Date of download: 11/12/2016 Copyright © The American College of Cardiology. All rights reserved. From: Effectiveness of In-Laboratory High-Dose Clopidogrel Loading Versus Routine Pre-Load in Patients Undergoing Percutaneous Coronary Intervention: Results of the ARMYDA-5 PRELOAD (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) Randomized Trial J Am Coll Cardiol. 2010;56(7): doi: /j.jacc Figure Legend: Secondary End Point Incidence of post-procedural elevation of creatine kinase-MB and troponin-I 1 to 3 times and >3 times above the upper normal limit.

Date of download: 11/12/2016 Copyright © The American College of Cardiology. All rights reserved. From: Effectiveness of In-Laboratory High-Dose Clopidogrel Loading Versus Routine Pre-Load in Patients Undergoing Percutaneous Coronary Intervention: Results of the ARMYDA-5 PRELOAD (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) Randomized Trial J Am Coll Cardiol. 2010;56(7): doi: /j.jacc Figure Legend: Safety Secondary End Point Bleeding/entry-site complications.

Date of download: 11/12/2016 Copyright © The American College of Cardiology. All rights reserved. From: Effectiveness of In-Laboratory High-Dose Clopidogrel Loading Versus Routine Pre-Load in Patients Undergoing Percutaneous Coronary Intervention: Results of the ARMYDA-5 PRELOAD (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) Randomized Trial J Am Coll Cardiol. 2010;56(7): doi: /j.jacc Figure Legend: Periprocedural Platelet Reactivity in the 2 Arms As measured by the VerifyNow assay, P2Y 12 reaction units (PRU) were similar pre-PCI, peak during PCI, and decline gradually at 2, 8, and 24 h. PCI = percutaneous coronary intervention.